KYTX · Kyverna Therapeutics, Inc.
$6.37
-0.02 (-0.31%)
At close · Oct 12
Return incl. dividend (before tax)
Market Cap
$395.18M
Shares
61.84M
Volume · Oct 12
31.36K
Avg daily vol (3M)
903.65K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.39
Open$6.20
Day$6.18–6.58
52W close$6.16–11.25
Avg vol 30d922K
Short int9.6M · 15.6% float · 8.9d
Short vol63%
Last earningsApr 22, 2026
DataFeb 2024–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$152.64M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$174.54M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+40.9%
Year over year · more shares
Price change (1Y)
-9.5%
Trailing year
Short interest
15.6%
Latest settlement · 8.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
−16%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
5%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−12%
trailing
6-month return
−43%
trailing
YTD return
−32%
this year
Relative strength
−53%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
2 of 120 funds reported for Sep 30 · net +583 sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.55% of float · ▲ +9.7% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
120 holders — near 2-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
EPS growth
−9%
Y/Y
Free cash flow
$-153.7M
Quant / Vol
risk profile
Volatility
91%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
5%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
2 of 120 funds reported for Sep 30 · net +583 sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.55% of float · ▲ +9.7% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
120 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $6 · 5%
Range high $11
vs 200-day avg -23%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KYTX
this stock
Kyverna Therapeutics, Inc.
|
$395.18M | -32.0% | — | — | 15.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KYTX | +2.7% | -12.0% | -43.2% | -6.0% | -32.0% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | +1.6% | -13.9% | -53.1% | -8.1% | -46.2% |